B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

•4.8% of MS patients fulfilled defined criteria for COVID-19-suspect group.•Two patients required hospitalization; no intubation or ICU admission was reported.•Patients on B-cell depleting agents had higher risk of being in the COVID-19-suspect group. To determine whether the course of COVID-19 is m...

Full description

Bibliographic Details

Published in:	Multiple sclerosis and related disorders Vol. 43; p. 102195
Main Authors:	Safavi, Farinaz, Nourbakhsh, Bardia, Azimi, Amir Reza
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.08.2020
Subjects:	B-cell depleting therapies COVID-19 DMTs Multiple Sclerosis Multiple Sclerosis COVID-19 DMTs B-cell depleting therapies
ISSN:	2211-0348, 2211-0356, 2211-0356
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!